Transcatheter valve replacement in the bicuspid valve is increasingly performed, but challenges remain

Transcatheter Valve Replacement in the Bicuspid Valve Is Increasingly Performed, but Challenges RemainAs experience increases, transcatheter aortic valve replacement (TAVR) has expanded to different populations and anatomies. This study sought to compare technical and clinical outcomes in patients with bicuspid versus tricuspid aortic stenosis from the Bicuspid AS TAVR Multicenter Registry.

 

Outcomes of 561 patients with bicuspid valves and 4546 patients with tricuspid valves were compared. Propensity score matching was used due to baseline differences, assembling 546 pairs of patients with similar baseline characteristics except for valve anatomy.

 

Patients who received bicuspid valves had more frequent conversion to surgery (2.0% vs. 0.2%; p = 0.006) and significantly lower device success rates (85.3% vs. 91.4%; p = 0.002).

 

A group of 320 patients with bicuspid aortic stenosis received first-generation valves (Sapiens XT and CoreValve) and presented recurrent aortic root injury with balloon-expandable devices (4.5% vs. 0.0%; p = 0.015) and more frequent moderate-to-severe paravalvular leak with self-expandable devices (19.4% vs. 10.5%; p = 0.02).

 

Among patients with second-generation devices (Sapiens 3, Evolut R, and Lotus), results with bicuspid and tricuspid valves were comparable.

 

The cumulative all-cause mortality rates at 2 years were comparable between bicuspid and tricuspid valves (17.2% 19.4%; p = 0.28).

 

Conclusion

Compared with patients who received tricuspid valves, transcatheter aortic valve replacement in patients who received bicuspid valves was associated with a similar prognosis, but lower device success rates. There were outcome differences in patients treated with first-generation balloon-expandable and self-expandable devices, whereas no differences were observed with second-generation devices.

 

Editorial

In this study, patients with bicuspid aortic stenosis were younger and presented less comorbidities than patients with tricuspid stenosis, and these differences required the use of propensity score matching.

 

Given the shift towards treating younger and lower surgical-risk patients with TAVR, the proportion of patients with bicuspid aortic stenosis assessed for valve replacement is likely to increase.

 

New devices have managed to limit differences between bicuspid and tricuspid stenosis, although the technical challenge will always be higher.

 

Original title: Outcomes in Transcatheter Aortic Valve Replacement for Bicuspid Versus Tricuspid Aortic Valve Stenosis.

Reference: Sung-Han Yoon et al. J Am Coll Cardiol 2017;69:2579-89.


Subscribe to our weekly newsletter

Get the latest scientific articles on interventional cardiology

We are interested in your opinion. Please, leave your comments, thoughts, questions, etc., below. They will be most welcome.

More articles by this author

Embolization of Left Atrial Appendage Closure Devices: Predictors, Prevention, and Management Strategies

Atrial fibrillation is associated with an increased risk of stroke and, in patients with contraindications to anticoagulation, percutaneous left atrial appendage closure represents an...

Coronary revascularization before TAVI: prior PCI or conservative management?

The coexistence of coronary artery disease (CAD) in patients with severe aortic stenosis undergoing TAVI is common, with a reported prevalence ranging from 30%...

Percutaneous Mechanical Aspiration versus Surgical Treatment of Tricuspid Valve Endocarditis

Tricuspid valve infective endocarditis (TVIE) accounts for approximately 5% to 10% of all cases of infective endocarditis. Surgical treatment remains the standard therapy in...

CRT 2026 | TAVI-CLOSE Trial: Dual Suture vs Suture + Plug for Vascular Closure After Transfemoral TAVI

The transfemoral approach is the predominant strategy for transcatheter aortic valve implantation (TAVI). Although vascular complications are currently less frequent, they remain relevant determinants...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

SOLACI Sessionsspot_img

Recent Articles

ACVC 2026 | CELEBRATE Trial: Prehospital Zalunfiban Use in STEMI

Optimizing antithrombotic therapy in the prehospital phase of ST-segment elevation myocardial infarction (STEMI) remains challenging due to the delayed onset of action of P2Y12...

ACVC 2026 | BOX Substudy: Mean Arterial Pressure Targets in Cardiogenic Shock After OHCA

Hemodynamic management of cardiogenic shock following ischemic out-of-hospital cardiac arrest (OHCA-AMICS) remains an unresolved issue, particularly regarding optimal mean arterial pressure (MAP) targets and...

ACVC 2026 | FLASH Registry European Cohort: Mechanical Thrombectomy in Pulmonary Embolism

The management of intermediate-high and high-risk pulmonary embolism (PE) remains an area of therapeutic uncertainty, particularly in patients with right ventricular (RV) dysfunction, in...